Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02116699 · ClinicalTrials.gov registry record · NA
Oropharyngeal Administration of Mother's Colostrum for Premature Infants (NS-72393-360)
A NA study, sponsored by Endeavor Health.
- Completed
- Registry status
- NA
- Development phase
- 260
- Enrollment target
NCT02116699 is a NA study that has completed, run by Endeavor Health. The registered enrollment target is 260 participants.
The verdict
NCT02116699, a NA study, has completed, sponsored by Endeavor Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 260 participants
- Enrollment target
Study Summary
Extremely premature (BW\<1250g) infants are at high risk for morbidity and mortality. Own mother's colostrum (OMC) and milk (OMM) protect against neonatal morbidity and are rich in immune factors which may provide immunostimulatory effects when administered oropharyngeally to extremely premature infants during the first weeks of life. The investigators hypothesize that infants who receive oropharyngeal mother's colostrum and milk will have significantly lower rates of infection and improved health outcomes, compared to infants who receive a placebo.
Interventions
- OTHER oropharyngeal mother's milk
- OTHER oropharyngeal sterile water
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2013-11-20 |
| Est. Completion | 2022-01-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02116699
The ClinicalTrials.gov registry entry for NCT02116699 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endeavor Health, which has 94 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which oropharyngeal mother's milk is the first listed.
NCT02116699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02116699 about?
NCT02116699 is a clinical study titled "Oropharyngeal Administration of Mother's Colostrum for Premature Infants (NS-72393-360)". Extremely premature (BW\<1250g) infants are at high risk for morbidity and mortality. Own mother's colostrum (OMC) and milk (OMM) protect against neonatal morbidity and are rich in immune factors which may provide immunostimulatory effects when administered oropharyngeally to extremely premature inf...
What is the current status of trial NCT02116699?
This trial is currently completed. It is a NA study. The enrollment target is 260 participants. The study started on 2013-11-20. Estimated completion is 2022-01-04.
What interventions are being tested in trial NCT02116699?
The interventions under investigation include: oropharyngeal mother's milk (OTHER), oropharyngeal sterile water (OTHER).
Who is sponsoring clinical trial NCT02116699?
This trial is sponsored by Endeavor Health, which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.